Sarah Collins
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Sarah Collins
Is Abbott Laboratories Trading at a High Valuation in September?
Abbott stock has been gaining momentum recently, and its valuation has improved.
Analysts Raise Target Prices on UNH Stock in September
Of the 23 analysts covering UNH stock, all of them have “buy” or “strong buy” recommendations for UnitedHealth Group.
Assessing BSX’s Recently Acquired Cryterion Cryoablation Platform
On July 5, Boston Scientific announced its acquisition of Cryterion Medical, which will add Cryterion’s cryoablation platform to BSX’s atrial fibrillation treatment portfolio.
Boston Scientific Expands Its AF Therapy Portfolio with Cryterion
Boston Scientific recently announced its acquisition of the remaining 65% stake in Cryterion Medical for $202 million in an up-front cash payment.
Discussing JNJ’s Strategy for Advancing Stroke Treatments
Strokes are one of the most prevalent life-threatening conditions, claiming one life every six seconds globally.
How Is JNJ Maintaining Its Momentum in Interventional Solutions?
JNJ’s interventional solutions business registered a year-over-year rise of 16.6% in the first quarter of 2018.
Discussing the Shift in Johnson & Johnson’s Research Strategy
Johnson & Johnson (JNJ) has made some changes to its R&D (research and development) strategy in its Medical Devices segment.
Pfizer’s Inlyta Expansion Thwarted by Failed Phase III Study
On April 11, 2018, Pfizer (PFE) said its ATLAS trial with Inlyta failed to show improvement in RCC disease-free survival.
MitraClip Drives Growth, Gets Reimbursement Approval in Japan
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.
Baxter International Completes Its Mallinckrodt Assets Buy
Baxter (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt for $185.0 million.
Teva’s Recent Launch of Generic Solodyn: What You Need to Know
On February 20, 2018, Teva Pharmaceutical announced the US launch of the generic version of Solodyn Extended Release tablets in two strengths.
How the Market Reacted to Teva’s Pricing of Its Generic Syprine
On February 9, 2018, Teva Pharmaceuticals (TEVA) announced the US launch of its generic version of 250 mg Syprine capsules.
The Key Factors in Dentsply Sirona Sales Growth Plan
Dentsply Sirona (XRAY) has delivered lower merger synergies than the company had estimated. It also took an impairment charge during 4Q17.
Understanding Dentsply Sirona’s New Organizational Structure
In 4Q17, Dentsply Sirona (XRAY) started reporting its operations under two segments, after a shift to three segments in fiscal 3Q17.
Medtronic Strengthens Diabetes Business with MiniMed Infusion Set
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set.
ABT Gets FDA Approval for World’s Smallest Mechanical Heart Valve
Abbott announced that it received FDA approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants.
Johnson & Johnson’s Acclarent Aera Balloon Dilation System
On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced FDA approval for the expanded indication for Acclarent Aera.
Align Technology to Execute on Key Strategic Priorities in 2018
Align Technology (ALGN) has been growing at a fast pace while it executes its strategic priorities around the world.
Align Technology’s Invisalign: Average Selling Price and Volumes
Increases in Align Technology’s (ALGN) Invisalign volumes and ASP were the major factors driving the company’s sales growth.
What Drove Medtronic’s Cardiac and Vascular Group in 3Q18
Cardiac and Vascular Group in fiscal 4Q17 Medtronic (MDT) reported total sales of ~$7.4 billion in fiscal 3Q18. Of that total, ~38% (~$2.8 billion) was contributed by Medtronic’s CVG (Cardiac and Vascular Group). CVG sales grew ~10% YoY (year-over-year) and ~7% on a constant-currency basis. US CVG sales grew ~6% YoY, while developed nation CVG sales […]
Abbott Laboratories’ LibreLink App in Europe
Abbott Laboratories (ABT) announced that it launched its Freestyle Librelink App in Europe.
A Look at Ablynx and Sanofi’s Existing Partnership
On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.
Why Abbott Laboratories’ Product Pipeline Is Expected to Boost 2018
R&D and product pipeline In fiscal 4Q17, Abbott Laboratories(ABT) invested ~6.9% of its total sales in R&D (research and development). In fiscal 2018, the company plans to invest ~7.5% of its total sales. Abbott Laboratories launched more than 20 new products in fiscal 2017. Abbott Laboratories now has an attractive product pipeline, boosted by the recent […]
Inside Abbott Laboratories’ 4Q17 Earnings Results: Key Highlights
Abbott Laboratories (ABT) reported sales of $7.6 billion and adjusted diluted EPS (earnings per share) of $0.74 for fiscal 4Q17.
Analyst Ratings for Thermo Fisher Scientific before 4Q17 Results
Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.
How Teva Pharmaceutical Is Realigning Organizational Structure
On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years.
Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet.
Align Technology’s Customer Acquisition Strategy Driving Market Growth
In 3Q17, Align Technology trained nearly 1,000 doctors in China.
Align Technology’s Growth Prospects amid Increasing Competition
The Chinese market is Align Technology’s major growth driver. However, the company is starting to witness strong competition from startups focused on the clear aligners market.
Edwards Lifesciences Expands Portfolio with Harpoon Medical Acquisition
On December 6, 2017, Edwards Lifesciences (EW) announced the completion of its acquisition of Harpoon Medical for $100 million in cash on December 1, 2017.
TMO’s Oncomine Dx Target Test Gets CMS Coverage
On December 7, 2017, Thermo Fisher Scientific (TMO) announced that its Oncomine Dx Target Test had been proposed for coverage by the CMS (Centers for Medicare & Medicaid Services).
Thermo Fisher Expands Its Partnership with Genome Diagnostics
In December 2017, Thermo Fisher Scientific (TMO) expanded its partnership with Genome Diagnostics (or GenDx), a Netherlands-based firm offering molecular diagnostics solutions.
Discussing the Recent Management Changes at Medtronic
On December 20, 12 of 24 analysts surveyed by Reuters rated Medtronic (MDT) stock as a “buy,” and the remaining 12 analysts recommended a “hold.” There were no “sell” ratings given to MDT stock.
Stryker’s Inorganic Growth Strategy Continues to Boost Growth
Stryker’s acquisition-driven growth strategy Stryker (SYK) has been growing at a fast pace through inorganic growth. It has undertaken a number of strategic acquisitions recently. In 3Q17, acquisitions contributed approximately 0.6% of the company’s YoY (year-over-year) sales growth, and in the first three quarters of 2017, Stryker acquisitions contributed ~3.2% of the company’s sales growth […]
How the Corporate Tax Rate Cut Could Affect R&D in the Medtech Industry
The repeal of the tax deduction for high medical expenses may reduce the number of taxpayers opting for costly medical technologies and services.
How the Medical Expense Tax Deduction Affects the Healthcare Industry
According to AARP, around 75% the population claiming these medical expense deductions from their income are 50 years or older.
Stryker’s FDA Approval Accelerates Neck Aneurysm Treatments
On November 9, 2017, Stryker (SYK) announced FDA approval for the Neuroform Atlas Stent System, which is approved for marketing under an HDE.
A Look at Varian Medical Systems’ Long-Term Objectives
Varian Medical Systems (VAR) spun off its imaging components business into Varex Imaging in January 2017, thus strengthening its positioning in the oncology market.
Emerging Markets Growth Is Driving Medtronic’s Geographic Strategy
In fiscal 2Q18, Medtronic registered sales of ~$1.1 billion from emerging markets.
Medtronic’s Disappointing MITG Business Performance in Fiscal 2Q18
Due to the disappointing fiscal 2Q18 results, Medtronic made a downward revision to its estimates for MITG sales growth in fiscal 2018 to 3.0%–3.5%.
What’s Driving BD’s Operating Margin Expansion
Overview BD (BDX) has registered strong operating margin expansion in recent years. Its margin improved by 100 basis points in fiscal 2015 and 200 basis points in fiscal 2016. In fiscal 2017, BD’s margin expanded by ~180 basis points. In 4Q17, BD’s operating margin grew ~14.6% YoY (year-over-year), limited by 700 basis points due to the divestiture of BD’s […]
Inside Abbott’s Neuromodulation Business Growth
Abbott’s Medical Devices segment has products for rhythm management, heart failure, electrophysiology, structural heart diseases, neuromodulation, and more.
Asia-Pacific Still Zimmer Biomet’s Strongest Geography
Zimmer Biomet Holdings witnessed a strong performance in its Asia-Pacific region. It contributed 16% to the company’s total sales.
How Mako Robots Are Driving Stryker’s Sales in 2017
Mako sales in 3Q17 In 3Q17, Stryker sold 33 Mako robots, compared with 30 robots in 3Q16. In 2Q17, Stryker installed 26 Mako robots. Of these 33 robots, 23 were installed in the United States. Around 40% of US sales are expected to be in competitive accounts. Stryker is training surgeons on its total knee application […]
How Intuitive Surgical Is Expanding Its Da Vinci X Systems Worldwide
Intuitive Surgical’s (ISRG) Da Vinci X received early FDA approval in May 2017 and was given a CE Mark in Europe in April 2017.
J&J Completed the Divestiture of Its Neurosurgery Business
Johnson & Johnson’s (JNJ) medical device business has been restructuring in order to focus on higher growth areas with potential expansion opportunities.
Chart in Focus: Baxter International’s Intralipid 20% Recall
On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.
What’s BD’s Latest News in the Diabetes Management Market?
On September 19, 2017, Becton, Dickinson, and Company (BDX), or BD, introduced a new pen needle for its pen injection devices.
Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval
On September 27, Abbott Laboratories (ABT) announced the FDA approval of its Flash CGM (continuous glucose monitoring) device, Freestyle Libre.
New Data Confirms the Efficiency of BSX’s HeartLogic Diagnostic
On September 19, 2017, Boston Scientific announced new data from its MultiSENSE (Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients) study.
